<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170116031972N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-11-14</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Effect of lavender essential oils and orange spring on pain, anxiety and restlessness</public_title>
      <acronym></acronym>
      <scientific_title>The effect of lavender essential oils and orange spring on pain, anxiety and restlessness of conscious patients admitted to intensive care units</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>105</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40827</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Samples were randomly assigned to intervention and control groups. The method of random allocation is such that the first sample is placed in one of three groups using the lottery, then according to the variables of sex and age (2 ±) and addiction in the three groups are matched. Assignment of samples will be continued using the lottery and according to the matched variables.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Pain in vigilant patients in the intensive care unit. Condition 2: Restlessness in vigilant patients in the intensive care unit. Condition 3: Anxiety in vigilant patients in intensive care units.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Placebo (normal saline) is used for patients of this group in addition to the routine care (if the patient is suffering from pain, restlessness and anxiety, sedatives and haloperidol will be used according to the physician's order. Also, the doctor may request psychiatric counseling for the patient). First, the patient completes the pain, anxiety and restlessness questionnaire. Then, the gauze impregnated with 5 drops of normal saline is placed at a distance of 10 cm from the patient's nose (we will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The pain, anxiety and restlessness questionnaire is recompleted by interviewing the patient immediately and one hour later. Intervention 2: First intervention group: The lavender essential oil is used in this group, in addition to the routine care. First, the questionnaires are completed by interviewing patients. Then, the gauze impregnated with 5 drops of the lavender oil is placed at a distance of 10 cm from the patient's nose (2%) (Made by Barij Essence of Kashan) (We will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The questionnaires are recompleted immediately and one hour later. Intervention 3: Second intervention group: The orange blossom essential oil is used in this group, in addition to the routine care. First, the questionnaire is completed by interviewing the patient. Then, the gauze impregnated with 5 drops of the orange blossom essential oil (2%) (Made by Barij Essence of Kashan) is placed in a distance of 10 cm from the patient’s nose (we will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The researcher will recomplete the questionnaires immediately and one hour later. It should be noted that sampling will be taken on the second day of the patient's admission to the intensive care unit. Also, sampling will be taken at 6-8 pm (due to reduced workload and patient's preparation for nighttime sleep). The questionnaires are completed by interviewing the patient. If the patient takes sedatives, the intervention will be done 3 hours later.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Results from this research are shared

When:
Start the access period 6 months after printing the results

To whom:
Researchers working in academic and scientific institutions and individuals in the industry

Conditions:
Data and results are presented after the request is reviewed

Where to obtain:
zahra karimzadeh
Zahrakarimzadeh1391@gmail.com

How to obtain:
The request will be sent in writing to the Zahrakarimzadeh1391@gmail.com email address, after the review will be delivered to the requesting person.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Karimzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Campus of the University of Medical Sciences, Beginning of the Road of Seven Gardens</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>76169-13555</zip>
        <telephone>+98 34 3132 5600</telephone>
        <email>Zahrakarimzadeh1391@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Karimzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Campus of the University of Medical Sciences, Beginning of the Road of Seven Gardens</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>76169-13555</zip>
        <telephone>+98 34 3132 5600</telephone>
        <email>Zahrakarimzadeh1391@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Able to read and write
Normal sense of smell
Stability of hemodynamic status
Failure to receive accommodation 3 hours before or during intervention
Absence of asthma and other chronic respiratory problems
Do not miss the last 24 hours
Absence of severe anxiety disorder with doctor's diagnosis
Lack of eczema and allergies to plant and citrus substances</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The need for a sedative or sedative during the intervention</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52</hc_code>
      <hc_code>R45.1</hc_code>
      <hc_code>F41.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
      <hc_keyword>Restlessness and agitation</hc_keyword>
      <hc_keyword>Other specified anxiety disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Placebo (normal saline) is used for patients of this group in addition to the routine care (if the patient is suffering from pain, restlessness and anxiety, sedatives and haloperidol will be used according to the physician's order. Also, the doctor may request psychiatric counseling for the patient). First, the patient completes the pain, anxiety and restlessness questionnaire. Then, the gauze impregnated with 5 drops of normal saline is placed at a distance of 10 cm from the patient's nose (we will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The pain, anxiety and restlessness questionnaire is recompleted by interviewing the patient immediately and one hour later.</i_keyword>
      <i_keyword>First intervention group: The lavender essential oil is used in this group, in addition to the routine care. First, the questionnaires are completed by interviewing patients. Then, the gauze impregnated with 5 drops of the lavender oil is placed at a distance of 10 cm from the patient's nose (2%) (Made by Barij Essence of Kashan) (We will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The questionnaires are recompleted immediately and one hour later.</i_keyword>
      <i_keyword>Second intervention group: The orange blossom essential oil is used in this group, in addition to the routine care. First, the questionnaire is completed by interviewing the patient. Then, the gauze impregnated with 5 drops of the orange blossom essential oil (2%) (Made by Barij Essence of Kashan) is placed in a distance of 10 cm from the patient’s nose (we will attach the gauze to the patient's collar). The patient is required to inhale it for 30 minutes. The researcher will recomplete the questionnaires immediately and one hour later. It should be noted that sampling will be taken on the second day of the patient's admission to the intensive care unit. Also, sampling will be taken at 6-8 pm (due to reduced workload and patient's preparation for nighttime sleep). The questionnaires are completed by interviewing the patient. If the patient takes sedatives, the intervention will be done 3 hours later.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Effect of lavender essential oils and orange spring on pain. Timepoint: The pain rate was completed before and immediately before the study, 1 hour after the intervention (placebo, lavender essential oil and orange spring). Method of measurement: VSA pain scale.</prim_outcome>
      <prim_outcome>Effect of lavender essential oils and orange spring on anxiety. Timepoint: The anxiety level was completed before the study immediately and 1 hour after the intervention (placebo, lavender and orange spring). Method of measurement: Spielberger Anxiety Inventory.</prim_outcome>
      <prim_outcome>Effect of lavender essential oils and orange spring on restlessness. Timepoint: The amount of restlessness was completed by the patient before and immediately and 1 hour after the intervention (placebo, lavender and orange spring). Method of measurement: Richmond Rescue Inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-06</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Campus of the University of Medical Sciences, Beginning of the Road of Seven Gardens kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
